viemed healthcare inc - VMD
VMD
Close Chg Chg %
7.29 0.01 0.14%
Closed Market
7.30
+0.01 (0.14%)
Volume: 79.78K
Last Updated:
Dec 24, 2025, 1:00 PM EDT
Company Overview: viemed healthcare inc - VMD
VMD Key Data
| Open $7.31 | Day Range 7.25 - 7.36 |
| 52 Week Range 5.93 - 8.62 | Market Cap $277.15M |
| Shares Outstanding 38.02M | Public Float 32.93M |
| Beta 1.21 | Rev. Per Employee N/A |
| P/E Ratio 22.08 | EPS $0.35 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 151.26K |
VMD Performance
| 1 Week | -1.62% | ||
| 1 Month | 5.64% | ||
| 3 Months | 8.79% | ||
| 1 Year | -10.54% | ||
| 5 Years | -8.75% |
VMD Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
2
Full Ratings ➔
About viemed healthcare inc - VMD
Viemed Healthcare, Inc. engages in the provision of home healthcare solutions. Through its subsidiaries, it supplies home medical equipment which provides post-acute respiratory services. It also offers respiratory disease management and in-home sleep testing and sleep apnea treatment. The company was founded by Casey Hoyt, Max Hoyt, and Michael Moore in 2016 and is headquartered in Lafayette, LA.
VMD At a Glance
Viemed Healthcare, Inc.
625 East Kaliste Saloom Road
Lafayette, Louisiana 70508
| Phone | 1-337-504-3802 | Revenue | 224.26M | |
| Industry | Hospital/Nursing Management | Net Income | 11.27M | |
| Sector | Health Services | 2024 Sales Growth | 22.539% | |
| Fiscal Year-end | 12 / 2025 | Employees | 1,179 | |
| View SEC Filings |
VMD Valuation
| P/E Current | 22.081 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 29.047 |
| Price to Sales Ratio | 1.459 |
| Price to Book Ratio | 2.389 |
| Price to Cash Flow Ratio | 8.37 |
| Enterprise Value to EBITDA | 7.893 |
| Enterprise Value to Sales | 1.42 |
| Total Debt to Enterprise Value | 0.022 |
VMD Efficiency
| Revenue/Employee | 190,209.50 |
| Income Per Employee | 9,554.707 |
| Receivables Turnover | 9.002 |
| Total Asset Turnover | 1.351 |
VMD Liquidity
| Current Ratio | 1.417 |
| Quick Ratio | 1.301 |
| Cash Ratio | 0.47 |
VMD Profitability
| Gross Margin | 58.736 |
| Operating Margin | 7.29 |
| Pretax Margin | 7.21 |
| Net Margin | 5.023 |
| Return on Assets | 6.787 |
| Return on Equity | 9.185 |
| Return on Total Capital | 8.148 |
| Return on Invested Capital | 8.692 |
VMD Capital Structure
| Total Debt to Total Equity | 5.226 |
| Total Debt to Total Capital | 4.966 |
| Total Debt to Total Assets | 3.878 |
| Long-Term Debt to Equity | 4.259 |
| Long-Term Debt to Total Capital | 4.047 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Viemed Healthcare Inc - VMD
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 117.06M | 138.83M | 183.01M | 224.26M | |
Sales Growth
| -10.85% | +18.60% | +31.82% | +22.54% | |
Cost of Goods Sold (COGS) incl D&A
| 44.50M | 55.16M | 71.62M | 92.54M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 11.31M | 15.63M | 21.89M | 24.00M | |
Depreciation
| 11.31M | 15.63M | 21.82M | 23.90M | |
Amortization of Intangibles
| - | - | 75.00K | 100.00K | - |
COGS Growth
| -14.44% | +23.96% | +29.82% | +29.21% | |
Gross Income
| 72.56M | 83.67M | 111.39M | 131.72M | |
Gross Income Growth
| -8.49% | +15.31% | +33.14% | +18.25% | |
Gross Profit Margin
| +61.98% | +60.27% | +60.87% | +58.74% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 62.15M | 76.06M | 95.98M | 115.20M | |
Research & Development
| 2.11M | 2.70M | 2.78M | 3.07M | |
Other SG&A
| 60.04M | 73.36M | 93.19M | 112.13M | |
SGA Growth
| +5.71% | +22.37% | +26.19% | +20.03% | |
Other Operating Expense
| (1.62M) | (989.00K) | (98.00K) | 173.00K | |
Unusual Expense
| (1.24M) | (935.00K) | 53.00K | 354.00K | |
EBIT after Unusual Expense
| 13.27M | 9.53M | 15.46M | 16.00M | |
Non Operating Income/Expense
| (448.00K) | (346.00K) | (645.00K) | 951.00K | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | (954.00K) | - |
Interest Expense
| 318.00K | 197.00K | 424.00K | 776.00K | |
Interest Expense Growth
| -37.52% | -38.05% | +115.23% | +83.02% | |
Gross Interest Expense
| 318.00K | 197.00K | 424.00K | 776.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 12.50M | 8.99M | 14.39M | 16.17M | |
Pretax Income Growth
| -52.57% | -28.10% | +60.08% | +12.36% | |
Pretax Margin
| +10.68% | +6.48% | +7.86% | +7.21% | |
Income Tax
| 3.38M | 2.77M | 4.15M | 4.76M | |
Income Tax - Current - Domestic
| (507.00K) | 1.02M | 5.59M | 8.60M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 3.88M | 1.75M | (1.44M) | (3.84M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | (954.00K) | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 9.13M | 6.22M | 10.24M | 11.41M | |
Minority Interest Expense
| - | - | - | 144.00K | - |
Net Income
| 9.13M | 6.22M | 10.24M | 11.27M | |
Net Income Growth
| -71.06% | -31.82% | +64.63% | +9.98% | |
Net Margin Growth
| +7.80% | +4.48% | +5.60% | +5.02% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 9.13M | 6.22M | 10.24M | 11.27M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 9.13M | 6.22M | 10.24M | 11.27M | |
EPS (Basic)
| 0.2311 | 0.161 | 0.2671 | 0.2907 | |
EPS (Basic) Growth
| -71.60% | -30.33% | +65.90% | +8.84% | |
Basic Shares Outstanding
| 39.49M | 38.66M | 38.35M | 38.75M | |
EPS (Diluted)
| 0.2243 | 0.1563 | 0.2537 | 0.2761 | |
EPS (Diluted) Growth
| -71.17% | -30.32% | +62.32% | +8.83% | |
Diluted Shares Outstanding
| 40.68M | 39.81M | 40.38M | 40.81M | |
EBITDA
| 23.34M | 24.23M | 37.40M | 40.35M | |
EBITDA Growth
| -23.56% | +3.80% | +54.38% | +7.87% | |
EBITDA Margin
| +19.94% | +17.45% | +20.44% | +17.99% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 13.00 | |
| Number of Ratings | 2 | Current Quarters Estimate | 0.13 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | 0.43 | |
| Last Quarter’s Earnings | 0.09 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.28 | Next Fiscal Year Estimate | 0.615 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 1 | 1 | 2 | 2 |
| Mean Estimate | 0.13 | 0.07 | 0.43 | 0.62 |
| High Estimates | 0.13 | 0.07 | 0.50 | 0.77 |
| Low Estimate | 0.13 | 0.07 | 0.36 | 0.46 |
| Coefficient of Variance | N/A | N/A | 23.02 | 35.64 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 2 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Viemed Healthcare Inc - VMD
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Viemed Healthcare Inc - VMD
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 24, 2025 | Michael Moore President | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 24, 2025 | Jeremy Trahan | 87,120 | Grant of rights | 0.00 |
| Jan 24, 2025 | William Todd Zehnder | 50,529 | Exercise of rights | 0.00 |
| Jan 24, 2025 | William Todd Zehnder | 69,508 | Exercise of rights | 0.00 |
| Jan 24, 2025 | William Todd Zehnder | 255,279 | Acquisition or disposition in the public market Non-derivative transaction at $8.15 per share | 2,080,523.85 |
| Jan 24, 2025 | William Todd Zehnder Chief Operating Officer; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 24, 2025 | William Todd Zehnder Chief Operating Officer; Director | 255,277 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.15 per share | 2,080,507.55 |
| Jan 24, 2025 | William Todd Zehnder Chief Operating Officer; Director | 261,038 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 24, 2025 | Michael Moore | 153,171 | Grant of rights | 0.00 |
| Jan 24, 2025 | Michael Moore | 50,529 | Exercise of rights | 0.00 |
| Jan 24, 2025 | Michael Moore | 69,508 | Exercise of rights | 0.00 |
| Jan 24, 2025 | Casey Hoyt Chief Executive Officer; Director | 242,949 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 24, 2025 | Michael Moore | 163,498 | Exercise of rights | 0.00 |
| Jan 24, 2025 | Michael Moore President | 157,737 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.15 per share | 1,285,556.55 |
| Jan 24, 2025 | Michael Moore President | 163,498 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 24, 2025 | Casey Hoyt | 223,560 | Grant of rights | 0.00 |
| Jan 24, 2025 | Casey Hoyt | 74,769 | Exercise of rights | 0.00 |
| Jan 24, 2025 | Casey Hoyt | 102,997 | Exercise of rights | 0.00 |
| Jan 24, 2025 | Casey Hoyt Chief Executive Officer; Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jan 24, 2025 | Casey Hoyt | 242,949 | Exercise of rights | 0.00 |